eGenesis
PrivateLast Round
Series D
Sep 4, 2024
Total Funding Raised
$454M
Company Overview
eGenesis is a biotechnology company that specializes in gene editing and genome engineering to revolutionize solid organ and therapeutic cell transplantation for life-threatening diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
eGenesis Comparables
Compare eGenesis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| United Therapeutics | 81% | |
| Makana Therapeutics | 79% | |
| NZeno | 79% |
For institutional investors. Book with your work email.
eGenesis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 4, 2024 | ||||
| Series C | Mar 2, 2021 | ||||
| Series B | Nov 7, 2019 | ||||
| Series A | Mar 16, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
eGenesis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SymBiosis Capital Management | Series C |
| Farallon Capital Management | Series D, Series C |
| LifeSci Venture Partners | Series C |
| Khosla Ventures | Series D, Series B, Series A, Series C |
| Parkwood | Series D |
| Eisai Innovation | Series D |
| Altium Capital | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Lead program EGEN-2784 in multi-patient Expanded Access study.
- Apr 18, 2026
Conducting clinical study for EGEN-2784 at Massachusetts General Hospital.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 22, 2026
Egenesis Inc. appoints Daniel Leblanc as Chief Manufacturing and Supply Officer on Oct 22nd '26, bringing more than 25 years of global biopharmaceutical experience to the role.
- is_developingSep 28, 2026
In the United States, Egenesis Inc. is currently developing programmes involving kidney transplantation, acute liver failure and heart transplantation as a clinical-stage, pre-revenue company using gene-editing technology to modify pig organs for potential human transplantation.
- receives_financingSep 28, 2026
On Sep 28th '26 in United States, Egenesis Inc. was proposed to receive Natco Pharma’s $16.7M investment through 8%-interest convertible promissory notes, expected to be completed by Oct 31st '26 to support research using gene-edited pig organs for human transplants.
- launchesAug 25, 2026
Egenesis Inc. announces the world's first FDA-authorized porcine kidney transplant in a living patient in Mar '24, advancing its development of transplantable organs through genome engineering.
For institutional investors. Book with your work email.
eGenesis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about eGenesis's valuation, stock price, and market status.
Is eGenesis a public or private company?
eGenesis is a private company.
What is the current stock price of eGenesis?
eGenesis is a private company, so its shares have no public market price. Caplight tracks eGenesis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is eGenesis worth (valuation)?
Valuation information for eGenesis is not publicly available.
Can I buy eGenesis stock?
eGenesis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was eGenesis's last funding round?
eGenesis's most recent funding round was Series D on September 4, 2024.
Who are the main investors in eGenesis?
Key investors in eGenesis include Osage University Partners, Lux Capital, Catalio Capital Management, Biomatics Capital Partners, Irving Investors.
Will eGenesis IPO soon?
No public IPO plans have been announced for eGenesis.
How can I track eGenesis secondary market activity?
Caplight tracks bids, offers, and trades in eGenesis's shares on secondary markets.